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Introduction
Chromosomal ends are protected from degradation and DNA 
repair activities by telomeres, formed by long double-stranded 
DNA (dsDNA) repeats and short single-stranded DNA (ssDNA) 
overhangs (Henderson et al., 1987; Henderson and Blackburn, 
1989). The length and structure of telomeres is maintained by 
two elongation mechanisms and six telomere-capping proteins. 
Telomere lengthening is mediated either by the telomerase, a 
ribonucleoprotein complex composed of the TERC RNA and 
the TERT reverse transcription (Greider and Blackburn, 1985), 
or by a telomerase-independent alternative lengthening of telo-
meres (ALT) mechanism based on homologous recombination 
between sister telomeres (Bryan et al., 1995; Henson et al., 
2002). The telomere-capping proteins, i.e., TRF1, TRF2, RAP1, 
TIN2, POT1, and TPP1 (de Lange, 2005; Songyang and Liu, 
2006), organize the telomere into a high-order structure. TRF1 
and TRF2 form homodimers that bind the dsDNA repeats via 
their myb domains (Bilaud et al., 1997; Broccoli et al., 1997). 
The ssDNA overhangs are protected by POT1 and TPP1 (Horvath 
et al., 1998; Wang et al., 2007; Xin et al., 2007). Within the 
complex, TRF1 and TRF2 are connected to POT1 via TIN2 and 
TPP1. TRF1 demonstrates the abilities to negatively control the 
telomere length (van Steensel and de Lange, 1997) and to regu-
late the mitotic entry of dividing cells (Shen et al., 1997). Its 
biological importance is highlighted by the early embryonic 
lethal  phenotype  of  TRF1-deficient  mice,  which  curiously 
shows no defect in telomere length (Karlseder et al., 2003).
The  other  side  of  this  story  is  represented  by  GNL3L 
(guanine nucleotide-binding protein-like 3), which belongs to a 
protein family of three, i.e., nucleostemin (NS), GNL3L, and 
Ngp-1. The common features of this family include an MMR1_
HSR1 domain and nucleolar distribution (Daigle et al., 2002; 
Leipe et al., 2002). NS was initially identified as an cancer and 
stem cell–enriched protein (Tsai and McKay, 2002). GNL3L 
and NS share the same invertebrate orthologue, whereas Ngp-1 
exists as a single-gene subfamily from yeast to human (Meng   
et al., 2007). All three proteins in the NS subfamily shuttle   
between the nucleolus and the nucleoplasm by a GTP-driven 
mechanism (Meng et al., 2007), which allows them to interact 
with proteins found in different subnuclear compartments. Despite 
their resemblance in primary protein sequences, NS, GNL3L, 
T
elomeric repeat binding factor 1 (TRF1) is a com-
ponent  of  the  multiprotein  complex  “shelterin,” 
which  organizes  the  telomere  into  a  high-order 
structure.  TRF1  knockout  embryos  suffer  from  severe 
growth defects without apparent telomere dysfunction, 
suggesting an obligatory role for TRF1 in cell cycle con-
trol. To date, the mechanism regulating the mitotic in-
crease  in  TRF1  protein  expression  and  its  function  in 
mitosis  remains  unclear.  Here,  we  identify  guanine   
nucleotide-binding protein-like 3 (GNL3L), a GTP-binding 
protein most similar to nucleostemin, as a novel TRF1- 
interacting  protein  in  vivo.  GNL3L  binds  TRF1  in   
the nucleoplasm and is capable of promoting the homo-
dimerization and telomeric association of TRF1, prevent-
ing promyelocytic leukemia body recruitment of telomere- 
bound TRF1, and stabilizing TRF1 protein by inhibiting 
its ubiquitylation and binding to FBX4, an E3 ubiquitin 
ligase  for  TRF1.  Most  importantly,  the  TRF1  protein- 
stabilizing  activity  of  GNL3L  mediates  the  mitotic  in-
crease of TRF1 protein and promotes the metaphase- 
to-anaphase transition. This work reveals novel aspects 
of TRF1 modulation by GNL3L.
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coIP results showed that GNL3L and TRF1 coexist in the same 
complex in vivo, captured from HeLa cell lysates by anti-GNL3L 
antibody (Fig. 1 B), and that their interaction does not depend on 
DNA or RNA (Fig. S1 A). To map the interactive domains of 
these two proteins, deletions of TRF1 were made on its N-terminal 
acidic domain (A), the homodimerization domain (HBD), an un-
defined region (UD), and the C-terminal myb domain (Fig. 1 D1). 
Affinity pull-down assays showed that HBD domain dele-
tion of TRF1 abolishes its binding to the GST-fused GNL3L 
(Fig. 1 D2). To define the TRF1-interactive domain of GNL3L, 
mutants lacking the N-terminal basic coiled-coil domain (B-C1), 
the GTP-binding domain (G), or the intermediate domain (I) of 
GNL3L were generated (Fig. 1 E1). GST-TRF1 binding assays 
revealed  that  interaction  between  TRF1  and  GNL3L  relies 
mostly on the G domain of GNL3L (Fig. 1 E2). These results 
demonstrate the importance of the HBD domain of TRF1 and 
the G domain of GNL3L in conferring their interaction.
GNL3L binding to TRF1 promotes TRF1 
homodimerization and is competed by TIN2
The GNL3L-interactive domain of TRF1 overlaps with its homo-
dimerization and TIN2-binding sites, suggesting a functional 
connection between GNL3L binding and the formation of TRF1 
protein complex. To test this idea, GST fusion proteins of TRF1 
were used to pull down lysates containing a fixed amount of 
Myc-tagged TRF1 admixed with increasing amounts of wild-
type or mutant GNL3L separately expressed in HEK293 cells 
(Fig. 2 A). In each sample, whole cell proteins were adjusted to 
the same level. The pull-down results showed that GNL3L 
increases the amounts of Myc-tagged TRF1 proteins bound 
by GST-TRF1 in a dose-dependent manner (Fig. 2 A1, Ret). 
and Ngp-1 display distinct dynamic properties (Meng et al., 
2007) and interactive proteins (Yasumoto et al., 2007), indica-
tive of their different biological activities.
We have previously shown that NS binds and facilitates 
the degradation of TRF1 protein (Zhu et al., 2006), and there-
fore are interested in knowing whether GNL3L or Ngp-1 also 
regulates TRF1. More recently the GNL3L’s role in telomere 
maintenance was reported by a study showing its isolation from 
the human telomerase complex and its overexpression effect in 
reducing the telomere length without affecting the telomerase 
activity  (Fu  and  Collins,  2007).  Here,  we  demonstrate  that 
GNL3L is capable of binding TRF1 independently of TERT. 
Evidence is presented for the activity of GNL3L to promote the 
homodimerization and telomeric retention of TRF1, reduce APB 
(ALT-associated PML body) formation, and increase TRF1 pro-
tein stability. The first two findings correlate with GNL3L’s 
ability to reduce the telomere length (Fu and Collins, 2007). 
The last result reveals a novel mechanism that stabilizes TRF1 
protein during mitosis and safeguards mitotic transition.
Results
TRF1 interacts with NS and GNL3L, but 
not with Ngp-1
To test whether GNL3L or Ngp-1 interacts with TRF1, coimmuno-
precipitation (coIP) experiments of Myc-tagged TRF1 and   
HA-tagged NS family proteins were performed in HEK293 cells 
(Fig. 1 A). The results showed that both NS and GNL3L, but not 
Ngp-1, can be coimmunoprecipitated with TRF1 by anti-Myc 
(row 1 and 2) or anti-HA antibody (row 3 and 4), and that none 
of the NS family proteins binds TIN2 (Fig. 1 C). Endogenous 
Figure 1.  Interaction between TRF1 and GNL3L is mediated by the homodimerization domain of TRF1 and the GTP-binding domain of GNL3L. (A) Cell 
lysates were extracted from HEK293 cells cotransfected with Myc-tagged TRF1 and HA-tagged nucleostemin (NS), GNL3L (G3L), or Ngp-1. Protein com-
plexes were immunoprecipitated (IP) by anti-tag antibodies and immunoblotted (IB) by the indicated antibodies. TRF1 interacts with NS and GNL3L, but not   
with Ngp-1. Arrows mark the precipitated TRF1. (B) Endogenous coIP confirmed that TRF1 and GNL3L co-reside in the same protein complex immuno-
precipitated by anti-GNL3L antibody (-G3L) from HeLa cell lysates. Pre-im: preimmune serum. (C) None of the NS family proteins interacts with TIN2.   
(D1, E1) Diagrams of TRF1 and GNL3L deletion mutants. Gray lines mark the deleted regions; numbers indicate amino acid positions. Domain abbreviations: 
A, acidic; HBD, homodimerization; UD, undefined; B, basic; C1 and C2, coiled-coil-1 and -2; G, GTP-binding; I, intermediate. GST pull-down assays 
demonstrated that the HBD domain of TRF1 (D2) and the G domain of GNL3L (E2) are required for the interaction of these two proteins. Agarose-retained 
(Ret) and supernatant fractions (Sup) are indicated.829 GNL3L REGULATES TRF1 • Zhu et al.
antibody. Our data showed that immunoprecipitation of GNL3L 
copurifies TRF1 but not TIN2 (Fig. 2 F1), and that only TRF1, but 
not  GNL3L,  is  coimmunoprecipitated  with  TIN2  (Fig.  2  F2). 
Therefore, TRF1 binds GNL3L and TIN2 separately. Finally, 
GNL3L binding to TRF1 or TERT is not affected by overexpres-
sion of TERT or TRF1, respectively (Fig. 2 G), and the GNL3L-
mediated TRF1 homodimerization is neither enhanced nor reduced 
by TERT overexpression (compare Fig. 2 H with Fig. 2 A1).
GNL3L increases the telomeric retention 
time of TRF1
To decide whether GNL3L binds TRF1 at or outside the telo-
mere, the distribution of TRF1 (GFP-tagged) and GNL3L (HA-
tagged) was examined in HeLa cells. Confocal studies showed 
that the TRF1 signal does not colocalize with the GNL3L signal 
in specific structures (Fig. 3 A), indicating that these two pro-
teins do not form stable complexes at the telomeric foci. Chro-
matin  immunoprecipitation  (ChIP)  assays  directly  addressed 
whether GNL3L binds telomeric DNAs and how it affects the 
telomeric  association  of  TRF1  at  steady  state.  ChIP  results 
showed that telomeric DNAs are not coimmunoprecipitated with 
This effect of GNL3L was abolished by deletion of its TRF1-
interactive G domain (G3dG; Fig. 2 A2) or the BC domain 
(G3dBC; Fig. 2 A3), but not by a point mutation (N166I) that 
abrogates  its  GTP-binding  ability  (Fig.  2 A4).  G3dBC  and 
N166I remain capable of binding TRF1 in the last two experi-
ments. To verify this result in vivo, four microRNA-adapted 
short hairpin RNA (shRNAmir) constructs (shG3-a to -d) were 
tested for their efficiencies to deplete the endogenous GNL3L 
protein (Fig. S2, A and B), and the shG3-a construct was chosen 
for its highest knockdown efficiency. Confirming the pull-down 
results, coIP assays showed that knocking down the endogenous 
GNL3L of HEK293 cells reduces the binding of FLAG- and 
Myc-tagged TRF1 compared with the shScr (which targets a 
scrambled sequence) knockdown samples (Fig. 2 B). GST pull-
down (Fig. 2 C) and knockdown coIP experiments (Fig. 2 D) 
showed that GNL3L has no obvious effect on the binding   
between TIN2 and TRF1. Conversely, GNL3L binding to TRF1 
was significantly reduced by TIN2 (Fig. 2 E). To determine 
whether TRF1 can bind GNL3L and TIN2 simultaneously, coIP 
experiments of GNL3L (HA), TRF1 (FLAG), and TIN2 (Myc) 
were conducted in HEK293 cells by anti-HA or anti-Myc   
Figure 2.  GNL3L promotes TRF1 homodimerization, and its binding to TRF1 is competed by TIN2. (A) Agarose-bound GST-TRF1 was incubated with cell 
lysates containing a fixed amount of Myc-tagged TRF1, mixed with increasing amounts of wild-type GNL3L (A1, G3L), the G3dG (A2), G3dBC (A3), or 
N166I mutant (A4). Wild-type GNL3L enhances the pull-down efficiency of Myc-tagged TRF1 by GST-TRF1 in a dose-dependent manner. Deleting the 
TRF1-interacting G domain (G3dG) completely abolishes this activity. (B) The coIP efficiency between FLAG- and Myc-tagged TRF1 was examined in control 
knockdown (shScr) and GNL3L knockdown (shG3-a) HEK293 cells by immunoprecipitation with anti-Myc antibody and immunoblotting with anti-FLAG 
antibody. The results confirmed that endogenous GNL3L promotes TRF1 homodimerization. (C) A small effect of GNL3L was observed on promoting the 
binding between Myc-tagged TIN2 and GST-TRF1. (D) This finding was supported by coIP of FLAG-tagged TRF1 and Myc-tagged TIN2 in the control (shScr) 
and GNL3L (shG3-a) knockdown HEK293 cells. (E) TIN2 binding significantly reduced the pull-down of GNL3L by GST-TRF1. (F) Protein complexes were 
immunoprecipitated from HEK293 cells cotransfected with GNL3L (HA), TIN2 (Myc), and TRF1 (FLAG) by anti-HA (F1) or anti-Myc antibody (F2). GNL3L, 
TIN2, and TRF1 proteins were detected by anti-tag antibodies in the IP or input fraction. The results showed that TRF1 does not bind GNL3L and TIN2 simul-
taneously. (G) Double and triple coIP of TRF1 (FLAG), TERT (Myc), and GNL3L (HA) showed that the coIP efficiency between TERT and GNL3L or between 
TRF1 and GNL3L is not affected by the coexpression of TRF1 or TERT1, respectively. (H) The ability of GNL3L to promote TRF1 homodimerization, measured 
by the GST-TRF1 pull-down of Myc-tagged TRF1 and compared with that in Fig. 2 A1, is not changed by TERT overexpression.JCB • VOLUME 185 • NUMBER 5 • 2009   830
TRF1 (Fig. 3 B, middle). This effect of GNL3L is specific for 
TRF1 but not for TRF2 (Fig. 3 B, right). Next, we used the 
FRAP  approach  to  investigate  how  GNL3L  regulates  the   
dynamic association between TRF1 and telomere in living cells. 
GNL3L compared with the control samples (Fig. 3 B, left).   
Compared with the TRF1-alone sample (3.58 ± 0.10, n = 3), co-
expression of GNL3L (4.82 ± 0.09, P = 0.0009) but not G3dG 
(3.84 ± 0.04, P = 0.09) shows increased telomeric bindings of 
Figure 3.  GNL3L increases telomeric retention of TRF1 in living cells. (A) Lack of nucleolar or telomeric colocalization of GFP-fused TRF1 (green) and HA- 
tagged GNL3L (red) in HeLa cells was shown by confocal analyses. The rectangular area is enlarged and shown on the right. Bars: 10 µm (left) and 2.5 µm 
(right). (B; left) ChIP assays showed that immunoprecipitation of HA-tagged GNL3L (G3L-HA/-HA) does not copurify telomeric DNAs (Tel-ChIP) more 
than the vector-transfected, -HA–precipitated sample (Ctrl/-HA), the GNL3L-transfected, IgG-precipitated sample (G3L-HA/IgG), or the copurified Alu   
sequence (Alu-ChIP). (Middle) Coexpression of GNL3L increases the association between TRF1 and telomeric DNAs (TRF1-Myc+G3L/-Myc) compared 
with the TRF1 alone or TRF1+G3dG transfections. (Right) GNL3L does not affect TRF2 binding to telomeric DNAs. All experiments were repeated three 
times. (C1) The C-terminally GFP-fused TRF1 (TRF1-gfp) colocalizes with the endogenous TRF2 in HeLa cells. High magnification of the indicated area 
(rectangle) is shown on the right. Bars: 10 µm (left) and 2 µm (right). (C2) Quantification of TRF1-gfp and TRF2 colocalization. All pixels are plotted based 
on their red (X-axis) and green (Y-axis) fluorescence intensities, and pseudocolored based on the event frequency, with red representing the highest and 
blue representing the lowest frequency. (D; left) FRAP analyses showed that GNL3L knockdown in HeLa cells increases the recovery rate and plateau 
level of TRF1-gfp at the telomere (red; P < 0.0001). Such phenotype can be rescued by the shG3-a–resistant full-length GNL3L (orange) but not by the 
shG3-a–resistant G3dG (green). RFI, relative fluorescence index. Error bars represent SEM shown on one side indicated by arrows. Top arrows mark the 
bleaching event. (Right) Time-sequenced images are shown with labels indicating the bleached telomere (yellow circles and arrows) and intervals between 
image acquisition and the bleaching pulse (in seconds). Bar: 2 µm. (E) The telomeric retention time of TRF1 was increased by overexpression of GNL3L 
(G3L) or G3dBC (P < 0.0001) but not by overexpression of G3dG. (F) GNL3L knockdown has no effect on the telomeric FRAP of TRF1-gfp in U2OS cells.   
(G) EMSA was performed using a (TTAGGG)6 probe and nuclear extracts from HEK293 cells expressing the indicated recombinant proteins (G2).   
A specific TRF1-probe complex was identified in lane 3 (black arrow), which could be competed by excess nonlabeled probes (lane 4) and supershifted by 
anti-Myc antibody (lane 5, gray arrow). Coexpression of GNL3L had no effect on the TRF1-probe complex (lane 9 and 10).831 GNL3L REGULATES TRF1 • Zhu et al.
that  GNL3L  coexpression  increases  the APB-negative  cells 
from 10.8% to 25.9% (P = 0.028, Fig. 4 A3, left), and reduces 
the percentage of APB/PML body from 40.6% to 23.4% (P < 
0.0001, middle) and the percentage of APB/TRF1
+ foci from 
7.9% to 4.2% (P < 0.0001, right). The total numbers of PML 
bodies and TRF1
+ foci per nucleus are 6.6 (± 0.3, SEM) and 
36.2 (± 1.1) in the control cells, and 6.4 (± 0.3, P = 0.63) and 
37.1 (± 1.0, P = 0.55) in the GNL3L-overexpressing cells, 
respectively, which excludes the possibility that the GNL3L-
dependent decrease of APB is caused by changes in the number 
of PML bodies or TRF1
+ foci. To confirm that the endogenous 
GNL3L also shows the same activity, we measured the GNL3L 
knockdown effect on TRF1-PML colocalization, and showed 
that GNL3L knockdown by shG3-a decreases the APB-negative 
cells from 8.9% to 1% (P = 0.031), and increases the percentage 
of APB/PML body from 37.2 to 57.6% (P < 0.0001) and the 
percentage of APB/TRF1
+ foci from 8.8 to 12.8% (P < 0.001) 
(Fig. 4 B). The total numbers of PML bodies (7.1 ± 0.2 vs. 6.8 ± 
0.2, P = 0.31) and TRF1
+ foci (33.8 ± 0.9 vs. 32.9 ± 0.8, P = 
0.49) per nucleus show no difference in the shScr and shG3-a–
treated cells. We also used TRF2 (4A794) and PML (H-238) 
colocalization to assess the GN3L effect on APB formation, 
and showed that GNL3L knockdown by siG3-2 increases the 
percentage  of APB/PML  body  from  66.2%  to  84.2%  (P  < 
0.0001) and the percentage of APB/TRF2
+ foci from 11.7% to 
15.0% (P < 0.001). Again, the total numbers of PML bodies 
(6.8 ± 0.2 vs. 6.8 ± 0.2, P = 0.96) and TRF2
+ foci (39.7 ± 1.0 vs. 
40.1 ± 1.1, P = 0.85) per nucleus remain the same in these two 
conditions. It should be noted that the baseline APB level is 
higher in the TRF2-PML than in the TRF1-PML measurement, 
which may be due to the differences of the antibodies used. 
Finally,  as  a  previous  study  showed  that  the  recruitment  of 
TRF1 to PML bodies is related to its SUMOylation (Potts and 
Yu,  2007),  the  effect  of  GNL3L  perturbation  on  TRF1   
SUMOylation was examined. In vivo SUMOylation assays showed 
that GNL3L overexpression does not affect the amount of   
SUMOylated TRF1 (Fig. S4), suggesting that this APB-reducing 
activity of GNL3L occurs after the TRF1 SUMOylation step.
GNL3L stabilizes TRF1 protein by reducing 
its ubiquitylation and FBX4 binding
To address how GNL3L affects the endogenous protein level 
of TRF1, HeLa cells were transfected with two previously 
described GNL3L-targeting siRNA duplexes (siG3-1 and siG3-2) 
(Yasumoto et al., 2007). Western blots showed that depleting 
the endogenous GNL3L by either siRNA duplex leads to a 
decrease in the endogenous TRF1 protein level, and that restor-
ing the expression of GNL3L by a siG3-2–resistant construct 
(G3L-siR,  Fig.  S2  E1)  can  effectively  reverse  the  siG3-2– 
induced TRF1 protein decrease (Fig. 5 A). To confirm this finding 
in a different cell type, H1299 stable cell lines with Dox-inducible 
GNL3L knockdown capabilities were established by cotrans-
fection of a doxycycline (Dox)-inducible shG3-a and a reverse 
Tet transactivator (rtTA-M2) construct (Fig. S2, C and D). Cell 
lysates were collected from the control (shScr) and GNL3L 
knockdown  (shG3)  cells,  receiving  either  no  treatment  or 
Dox treatment for 4, 7, and 10 d. Western analyses confirmed a 
Because the telomere-bound TRF1 is constantly exchanged with 
the  unbound  TRF1  in  the  nucleoplasm,  the  more  stable  the 
TRF1–telomere association is, the longer the telomeric retention 
time of TRF1 will be and hence the slower the recovery rate after 
photobleaching. The FRAP paradigm was set up such that a 
single telomere was bleached and its fluorescence recovery was 
recorded.  The  validity  of  using  the  C-terminally  GFP-fused 
TRF1 to track the movement of endogenous TRF1 protein in 
living cells was supported by the results showing that its distri-
bution coincides with that of endogenous TRF2 (Fig. 3 C) and 
that its dynamic property is the same as that of the N-terminally 
GFP-fused TRF1 (Fig. S3). FRAP analyses showed that GNL3L 
depletion by shG3-a significantly increases the FRAP recovery 
rate and the plateau level of TRF1 (P < 0.0001 by repeated mea-
sures ANOVA, Fig. 3 D). This GNL3L knockdown FRAP 
phenotype can be specifically rescued by the shG3-a–resistant 
full-length GNL3L (shG3+G3L) but not by the shG3-a–resistant 
G3dG mutant (shG3+G3dG) (Fig. 3 D and Fig. S2 E2). Consis-
tently, the FRAP recovery rate of TRF1 was reduced by co-
expression of the wild-type and G3dBC mutant of GNL3L (P < 
0.0001) but not by coexpression of the non-TRF1-binding G3dG 
mutant (P = 0.933) (Fig. 3 E). The ability of GNL3L to enhance 
the telomeric retention of TRF1 was not observed in telomerase
 
U2OS cells (Fig. 3 F), indicating that this effect may be cell 
type– or telomerase-dependent. Finally, we used the electro-
phoretic mobility shift assay (EMSA) to check how GNL3L 
affects the DNA-bound TRF1 in vitro. EMSA was conducted 
with  a  radiolabeled  probe  containing  six  tandem  repeats  of 
TTAGGG and nuclear extracts expressing the indicated proteins 
(Fig. 3 G2). Compared with the probe alone (lane 1) and vector-
transfected cell lysate samples (lane 2), the Myc-tagged TRF1-
transfected  sample  (lane  3)  yields  a  specific  TRF1–probe 
complex  (black  arrow)  that  can  be  competed  by  excess  un-
labeled probes (lane 4) and supershifted by anti-Myc antibody 
(lane 5, gray arrow) (Fig. 3 G1). GNL3L by itself does not 
produce specific shifted complexes (lane 7 and 8). Neither 
does coexpression of GNL3L supershift or affect the TRF1–
probe complex (lane 9 and 10). These results demonstrate that 
although GNL3L is not a component of the final TRF1 complex 
at telomeres, it helps stabilize the telomeric association of TRF1 
in HeLa cells.
GNL3L negatively regulates APB formation 
in ALT (e.g., U2OS) cells
In U2OS cells, telomere elongation does not require telomerase, 
but instead is associated with the formation of APB. APB con-
tains telomeric DNAs, TRF1, and various other telomere pro-
teins (Yeager et al., 1999; Potts and Yu, 2007). We therefore 
reason that GNL3L may regulate the APB formation in ALT 
cells. To test this idea, the telomeric foci and promyelocytic 
leukemia (PML) bodies of GNL3L-perturbed U2OS cells were 
labeled by TRF1-GFP and anti-PML (PG-M3) antibody, respec-
tively. Colocalization of TRF1 and PML signals was deter-
mined based on 3D reconstruction of confocal images of 1-µm 
optical thickness serially sampled at 0.5-µm intervals along the 
Z-axis (Fig. 4, A1–2 and B1–2). Analyses of 95–100 randomly 
sampled cells from five independent experiments demonstrated JCB • VOLUME 185 • NUMBER 5 • 2009   832
HEK293 cells were cotransfected with fixed amounts of Myc-
tagged TRF1 and GFP, both driven by the same EF1 promoter, 
and increasing amounts of HA-tagged GNL3L. Compared with 
the GFP protein, the levels of exogenously expressed TRF1 pro-
tein are also increased by coexpression of GNL3L in a dose- 
dependent manner (Fig. 5 C), indicating that the GNL3L effect on 
Dox-dependent reduction of GNL3L protein in the shG3 cells 
but not in the shScr cells, and most importantly a decrease of the 
endogenous TRF1  protein  in  the  GNL3L-depleted  samples 
(Fig. 5 B). By contrast, the TRF2 protein level was unchanged 
by GNL3L knockdown. To determine whether GNL3L in-
creases TRF1 at the transcriptional or posttranscriptional level, 
Figure 4.  GNL3L negatively regulates APB formation in U2OS cells. (A) APB formation in U2OS cells was scored by colocalization of TRF1-gfp and PML 
bodies in the control (A1) or GNL3L-overexpression U2OS cells (A2). Serial confocal images of 1-µm thickness were collected at 0.5-µm intervals and 
reconstructed along the X-Y, X-Z, and Y-Z planes for individual cell. Arrows indicate overlapped spots. (A3) Coexpression of GNL3L increases the percent-
age of APB-minus cells, and decreases the ratios of APB/PML bodies and APB/TRF1
+ foci. (B) Colocalization of TRF1
+ foci and PML bodies was measured 
in control (shScr, B1) or GNL3L knockdown (shG3-a, B2) U2OS cells. (B3) GNL3L knockdown increases colocalization of TRF1 foci and PML bodies.   
(C) GNL3L knockdown by siG3-2 promotes APB formation in U2OS cells, as scored by colocalization of TRF2
+ foci and PML bodies.833 GNL3L REGULATES TRF1 • Zhu et al.
samples (Fig. 5 F, top two panels, P < 0.0001). This GNL3L 
knockdown phenotype of TRF1 destabilization can be specifi-
cally rescued by the shG3-a–resistant full-length GNL3L but 
not by the shG3-a–resistant G3dG (Fig. 5 F, bottom). Because 
the TRF1 protein is degraded by the ubiquitin-proteasome path-
way (Chang et al., 2003), an in vivo ubiquitylation assay was 
used to decide how GNL3L influences the ubiquitylation of 
TRF1 (Fig. 5 G). Compared with the control-transfected sample 
(lane 3), overexpression of wild-type GNL3L (lane 4) or the 
G3dB mutant (lane 5) significantly reduces TRF1 polyubiquity-
lation, whereas the G3dG (lane 6) and N166I (lane 7) mutants 
do not, concurring with the ability of wild-type and mutant 
GNL3L to increase TRF1 protein (Fig. 5 D). In support of this 
finding, knocking down the endogenous GNL3L by the shG3-a 
or shG3-b construct increases the ubiquitylation of TRF1 to a 
TRF1 protein occurs posttranscriptionally. This gain-of-function 
phenotype may depend on the overexpression level of GNL3L 
because  a  threefold  increase  of  GNL3L  by  G3L-siR  is  not 
enough to elicit this effect (Fig. 5 A). It should be noted that this 
activity of GNL3L requires its N166 residue and G domain but 
not the BC-domain (Fig. 5 D).
To investigate if GNL3L regulates TRF1 protein stability, 
HEK293 cells were transfected with TRF1. 36 h later, cells were 
treated with cycloheximide (CHX, 100 g/ml), and lysates were 
collected at 2-h intervals from 0 to 12 h. Western results showed 
that TRF1 proteins in the GNL3L overexpression cells are de-
graded much more slowly than that in the control cells (Fig. 5 E, 
P < 0.0001 by repeated measures ANOVA). In consistence, the 
protein stability of TRF1 is significantly reduced in the shG3-a– 
transfected HEK293 cells compared with the shScr-treated 
Figure 5.  GNL3L stabilizes TRF1 protein by preventing its ubiquitylation and binding to FBX4. (A) Knocking down the endogenous GNL3L expression by 
siG3-1 or siG3-2 in HeLa cells reduces the endogenous TRF1 protein level, which can be rescued by an siG3-2–resistant GNL3L (G3L-siR). (B) The same   
result was confirmed in H1299 cells by using the Doxycycline (Dox)-inducible shRNAmir knockdown approach. Western analyses show a time-dependent 
reduction of GNL3L protein in the Dox-treated GNL3L knockdown (shG3) cells, but not in the Dox-treated shScr cells. Specifically, GNL3L depletion decreases 
the protein level of TRF1 but not that of TRF2. (C) Overexpression of GNL3L (HA) increases the protein level of TRF1 (Myc) in a dose-dependent manner after 
normalization by the protein level of GFP cotransfected in the same sample. (D) The GNL3L’s ability to increase TRF1 protein is abolished by deleting its 
TRF1-interactive G domain and by the N166I mutation, but not by the BC domain deletion. (E) TRF1 protein stability was measured by a protein degrada-
tion assay in control (Ctrl) and GNL3L-overexpressing (G3L, HA-tagged) HEK293 cells. The TRF1 protein amounts were measured from three experiments, 
adjusted based on their -tubulin (Tub) amounts, and expressed as percentages of the TRF1 protein amount at the 0-h time point. (F) GNL3L depletion by 
shG3-a increases the protein degradation of TRF1 (top two panels), which can be rescued by coexpression of an shG3-a–resistant full-length GNL3L but 
not an shG3-a–resistant G3dG mutant (bottom panel). (G) Overexpression of the wild-type (lane 4) or G3dBC mutant (lane 5) of GNL3L decreases TRF1 
ubiquitylation compared with the control sample (lane 3), whereas the G3dG (lane 6) and N166I mutants (lane 7) have no such effect. (H) GNL3L deple-
tion by shG3-a (lane 4) increases the ubiquitylation of TRF1, which can be reversed by overexpression of an shG3-a–resistant GNL3L (G3L-shR, lane 6).   
(I) CoIP experiments showed that GNL3L (HA) binding to TRF1 (FLAG) decreases the coIP efficiency between TRF1 and FBX4 (Myc).JCB • VOLUME 185 • NUMBER 5 • 2009   834
is unknown. To determine whether GNL3L is involved in this 
process, we first measured the protein level of endogenous TRF1 
and GNL3L in the nontreated (Ctrl), S phase–synchronized, and 
M phase–synchronized HEK293 cells (Fig. 6 A, left). Compared 
with the control and S phase cells, the endogenous protein levels 
of TRF1 and GNL3L were both increased in the M phase cells, 
whereas NS remained unchanged. The same result was observed 
in HeLa cells (not depicted), as well as with exogenously   
expressed Myc-tagged TRF1 proteins (Fig. 6 A, right), suggest-
ing that a posttranscriptional mechanism is involved. Impor-
tantly, this mitotic increase of TRF1 protein was abolished when 
GNL3L was depleted by siG3-1 or siG3-2, and restored by co-
expression of the siG3-2–resistant GNL3L construct (G3L-siR) 
(Fig. 6 B). In addition, we found that not only did the protein 
levels of GNL3L and TRF1 increase, but their binding was also 
enhanced during mitosis (Fig. 6 C), which is consistent with the 
degree compatible with their protein knockdown efficiencies, 
and the increased TRF1 ubiquitylation by shG3-a can be   
reversed by coexpression of an shG3-a–resistant GNL3L con-
struct (G3L-shR) (Fig. 5 H). Ubiquitylation of TRF1 requires 
an E3 ubiquitin ligase component FBX4 (Lee et al., 2006). CoIP 
assays  showed  that  FBX4  binding  to  TRF1  is  impeded  by 
GNL3L (Fig. 5 I), indicating that GNL3L inhibits TRF1 ubiqui-
tylation by preventing its association with the E3 ubiquitin 
ligase complex.
GNL3L stabilizes TRF1 protein during 
mitosis and promotes metaphase-to-
anaphase transition
The protein level of TRF1 is up-regulated during mitosis and 
down-regulated in the G1 phase (Shen et al., 1997). So far, the 
mechanism responsible for the mitotic increase of TRF1 protein 
Figure 6.  GNL3L stabilizes TRF1 protein during mitosis and promotes the metaphase-to-anaphase transition. (A) The protein amounts of endogenous TRF1 
(left) and exogenously expressed TRF1 (Myc-tagged, right) were measured in the nontreated (Ctrl), S phase-synchronized (S), and M phase-synchronized 
HEK293 cells. (B) GNL3L depletion by siG3-1 and siG3-2 abolishes the mitotic increase of TRF1 protein. This effect of siG3-2 can be reversed by coexpres-
sion of a siG3-2–resistant GNL3L (G3L-siR). (C) In addition to the increase in protein level, the binding efficiency between GNL3L and TRF1 is also increased 
during mitosis. To control for the mitotic increase of TRF1 and GNL3L proteins, their input amounts in each sample were adjusted to the same before coIP. 
(D) PI-labeled cell cycle analyses showed that GNL3L knockdown in HeLa (D1) or HEK293 cells (D2) increases the percentage of G2/M phase cells.   
A mild decrease in the G1 cell percentage and an increase in the sub-G1 cell percentage were also noticed. (E) The percentages of cells at different mitotic 
stages were scored by anti–phospho-Histone H3 (pH3) staining in control and GNL3L knockdown HeLa (E1) and HEK293 cells (E2). Over 1.6 × 10
4 cells 
from eight independent experiments were collected for each sample. The results showed that GNL3L depletion triggers cell cycle arrest at the metaphase-
to-anaphase transition, and this effect can be rescued by coexpression of the siG3-2–resistant GNL3L (G3L-siR) or TRF1. Cells cotransfected with siG3-2   
and G3L-siR (in both HeLa and HEK293 cells) or with siScr and TRF1 (in HeLa cells only) showed decreased prophase cell percentages. *, P < 0.01;   
**, P < 0.001; ***, P < 0.0001. (F) Silencing GNL3L expression increases the amount of phospho-cdc2 (Tyr15), supporting a role of GNL3L in the pro-
phase entry of dividing cells as well.835 GNL3L REGULATES TRF1 • Zhu et al.
mitosis, its telomeric signal becomes relatively less intense in 
the metaphase, anaphase, and telophase cells compared with their 
neighboring interphase and prophase cells imaged in the same 
field (Fig. 7 A). This phenomenon is also true for the GFP-
tagged TRF1 when expressed at a low level (Fig. S5 A), arguing 
against the possibility that during this mitotic window, the telo-
meric TRF1 may undergo modification or be masked by its 
interacting protein, which prevents the epitope recognition of 
the anti-TRF1 antibody (TRF-78). This conclusion is further 
bolstered by the staining patterns of another anti-TRF1 anti-
body (C-19, Fig. S5 B) and anti-TRF2 antibody (Fig. S5 C), 
which show similar distributions during mitosis, although the 
sensitivity and specificity of the C-19 anti-TRF1 antibody is 
less than optimal. It should be noted that the GFP-tagged TRF1 
also concentrates at the telomere when its expression level is 
high, indicating that TRF1 is not completely absent from the 
telomere during mitosis. On the other hand, the GNL3L signal 
becomes diffuse and colocalized with TRF1 during this mitotic 
window (Fig. S5 D). To define the mitotic defect associated 
with GNL3L knockdown, mitotic spindles and chromosomes 
were  visualized  by  anti–-tubulin  immunofluorescence  and 
H2B-GFP in GNL3L-depleted cultures. Notably, we have found 
that both the GNL3L and TRF1 knockdown cultures contain 
more cells with multipolar spindles than do the control knock-
down cultures, and that their centromeres, shown by anti–
CENP-A immunostaining, are well aligned along the multipolar 
metaphase plate (Fig. 7 B).
Discussion
This  study  focuses  on  a  novel  GNL3L-regulated  control  of 
TRF1 complex formation and protein modification (Fig. 7 C). 
We showed that TRF1 interacts with GNL3L via its HBD 
domain and the G domain of GNL3L. On one hand, GNL3L 
decreases  the  degradation  of TRF1  by  preventing  its  FBX4 
binding and ubiquitylation, thereby allowing the TRF1 protein 
to accumulate during mitosis (Fig. 7 C1). On the other hand, 
GNL3L promotes the homodimerization and telomeric reten-
tion of TRF1 in telomerase
+ cells (Fig. 7 C2, top), and nega-
tively regulates APB formation in telomerase
 cells (bottom). 
Mutant analyses reveal that loss of GTP binding (i.e., by the 
N166I mutation) affects the protein stabilization but not the 
homodimerization activity of GNL3L on TRF1. The differential 
effects of the N166I mutant on TRF1 stability and homodimer-
ization indicate that TRF1 homodimerization, by itself, is not 
sufficient to prevent its degradation.
Dynamic interaction between  
GNL3L and TRF1
In interphase cells, GNL3L resides mainly in the nucleolus and 
less in the nucleoplasm, whereas TRF1 is concentrated at the 
telomere. At steady state, there is a constant exchange between 
the nucleolar and the nucleoplasmic pools of GNL3L (Meng 
et al., 2007), as well as between the telomeric and the nucleo-
plasmic pools of TRF1 (Mattern et al., 2004). Several scenarios 
can be envisioned for the binding of these two proteins and their 
subsequent journey within the nucleus. After their initial association 
idea that the nucleolus is dissembled during mitosis, thereby 
releasing more GNL3L into the nucleoplasm for TRF1 binding.
To uncover the biological role of GNL3L in cell cycle 
regulation, its loss-of-function effect was analyzed by flow 
cytometry in HeLa cells (Fig. 6 D1). The FACS results showed 
that the main effect of GNL3L knockdown is to increase the 
G2/M phase cell percentage (P < 0.01, n = 8). Together with a 
mildly decreased G1 cell percentage (P = 0.07), this finding 
indicates that GNL3L depletion causes cell cycle arrest at or 
before the mitotic exit. The same findings of G2/M increase 
(P = 0.01) and G1 decrease (P = 0.06) were observed in HEK293 
cells, although the difference in the G2/M percentage caused by 
GNL3L knockdown was less than that in HeLa cells (Fig. 6 D2). 
To  further  define  the  time  point  within  the  G2/M  phase   
affected  by  GNL3L  knockdown,  different  phases  of  mitotic 
cells were scored by anti-phospho-Histone H3 (pH3) staining in 
control and GNL3L knockdown HeLa cells (Fig. 6 E1) and 
HEK293 cells (Fig. 6 E2). Our results consistently showed that 
GNL3L knockdown causes a significant decrease in the per-
centages of anaphase and telophase cells compared with the 
siScr-treated samples (P < 0.0001), and that this GNL3L knock-
down phenotype can be completely rescued by coexpression of 
G3L-siR (P < 0.001). Despite the decrease of anaphase and 
telophase cells by GNL3L knockdown, a concurrent increase of 
metaphase or prophase cells is not seen, suggesting a potential 
blockage before the prophase. This idea is supported by an 
increased phospho-cdc2 (p-cdc2, Tyr15) level in the GNL3L 
knockdown samples (Fig. 6 F). To determine whether this func-
tion of GNL3L in promoting the metaphase-to-anaphase transi-
tion is related to TRF1 stabilization, we also tested the ability of 
TRF1 to rescue the mitotic phenotype of GNL3L knockdown. 
First, to minimize the possibility of introducing adverse or addi-
tive effects by TRF1 overexpression, we controlled the expres-
sion of Myc-tagged TRF1/Pin2 at a level two times that of the 
endogenous TRF1 (Fig. S2 F), and showed that expressing this 
amount of TRF1 protein in siScr-treated cells does not alter 
their anaphase and telophase cell percentage (P = 0.34 for HeLa 
cells and 0.86 for HEK293 cells). Notably, restoring this amount of 
TRF1 significantly rescues the stalled metaphase-to-anaphase 
transition  caused  by  GNL3L  knockdown  in  both  HeLa  and 
HEK293 cells (P < 0.01). It is worth noting that although co-
expression of TRF1 does not affect the percentages of metaphase, 
anaphase, and telophase cells, it reduces the prophase cell per-
centage to some extent in the control knockdown HeLa cells 
(P = 0.06) but not in the siG3-2 knockdown cells. The same 
effect is observed with G3L-siR coexpression in GNL3L knock-
down HeLa and HEK293 cells (P < 0.01), suggesting that per-
turbation of GNL3L or TRF1 may dysregulate the prophase 
entry of dividing cells as well.
Knockdown of GNL3L or TRF1 increases 
cells with multipolar mitotic spindle
To determine their site of action during the metaphase-to-anaphase 
transition, protein localization of TRF1 was revealed by high-
resolution confocal analysis in HeLa cells stably expressing a 
GFP-tagged H2B (Kanda et al., 1998). Our results showed that 
although the total protein level of TRF1 increases during   JCB • VOLUME 185 • NUMBER 5 • 2009   836
As GNL3L is also copurified with the telomerase complex, we 
provide evidence to show that its abilities to bind TRF1 and to 
regulate the homodimerization and APB formation of TRF1 are 
independent of its interaction with TERT. Because the telomerase 
is a multicomponent complex, the involvement of other telo-
merase components in the GNL3L–TRF1 interaction cannot be 
completely ruled out as yet. In addition, the GNL3L’s ability to 
increase the telomeric retention of TRF1 is seen in HeLa cells 
but not in U2OS cells, which could mean that either this pheno-
type requires the presence of telomerase or occurs in a cell 
type–specific manner.
Roles of GNL3L in the mitotic progression
A much-debated function of TRF1 is in the regulation of mitotic 
transit, which coincides with a surge of its protein level during 
mitosis (Shen et al., 1997). TRF1 overexpression was shown to 
increase the G2/M percentage of cells (Shen et al., 1997) and the 
apoptotic percentage in cells with short telomeres (Kishi et al., 
2001). Our work demonstrates that the protein level and TRF1 
binding of GNL3L both increase during mitosis, and that GNL3L 
is responsible for the mitotic increase of TRF1 protein. In addi-
tion, GNL3L is needed for the metaphase-to-anaphase transi-
tion, and this activity of GNL3L is partially mediated by TRF1. 
in the nucleoplasm, GNL3L can either carry TRF1 protein to 
the nucleolus or simply modify and release it on-site. Alterna-
tively, GNL3L itself may participate in the assembly of the   
telomere-capping complex. The fact that overexpression of TRF1 
and GNL3L does not increase the nucleolar signal of TRF1 or 
the telomeric signal of GNL3L and that GNL3L is not associ-
ated with telomeric DNAs argue against the first and third pos-
sibilities. Supporting the notion that GNL3L is not part of the 
stable telomeric complex, binding and coIP experiments show 
that TRF1 does not bind simultaneously with GNL3L and TIN2, 
an essential component of the shelterin complex. We propose 
that GNL3L may function as a chaperone protein that regulates 
the  complex  formation  and  posttranslational  modification  of 
TRF1 protein. Although this regulatory event occurs in the 
nucleoplasm, it will influence the availability and readiness of 
TRF1 for its telomere-capping action. This idea somewhat   
resembles the explanation proposed by Fu and Collins (2007) 
for  why  GNL3L  overexpression  shortens  telomere  length 
without apparently affecting the activity of telomerase, that is, 
binding of GNL3L may sequester the telomerase RNP in the 
nucleoplasm, rendering it biologically inactive in vivo. One 
notable difference between this model and ours is that GNL3L 
increases rather than decreases TRF1 binding to the telomere. 
Figure 7.  Knockdown of GNL3L or TRF1 increases the number of cells with multipolar spindle. (A) Distribution of endogenous TRF1 protein at different 
stages of mitosis is shown by high-resolution confocal analyses of anti-TRF1 (TRF-78) staining in H2B-GFP HeLa cells. Bar: 5 µm. (B1 and B2) GNL3L or TRF1 
knockdown significantly increases the number of cells with multipolar spindle, shown by -tubulin immunostaining (Tub). Y-axis shows the percentage of 
metaphase cells with multipolar spindle. *, P < 0.01; **, P < 0.001. The centromeres in these cells, labeled by anti–CENP-A antibody, are aligned along 
the multipolar metaphase plate. TRF1 knockdown efficiency was shown in B3. (C) Models of GNL3L-mediated regulation of TRF1 protein modification and 
function in mitotic transition (C1) and telomere maintenance (C2).837 GNL3L REGULATES TRF1 • Zhu et al.
GNL3L regulates telomeric association 
and PML body recruitment of TRF1 in 
interphase cells
A well-known function of TRF1 is to maintain the telomeric 
structure and negatively control the telomeric length by denying 
the telomeric access of telomerase (van Steensel and de Lange, 
1997). Our study showed that GNL3L increases the homo-
dimerization, the protein stability, and the telomeric association 
of  TRF1. An  interesting  note  of  our  FRAP  findings  is  that 
GNL3L knockdown influences both the recovery rate and the 
plateau level of telomere-bound TRF1, which is consistent with 
the idea of two populations of TRF1 residing at the telomere 
(Kim et al., 2008). Because GNL3L overexpression affects the 
loosely bound (or dynamic) fraction more than the stable frac-
tion, we suggest that the amount of stably bound TRF1 at the 
telomere may be controlled by other protein(s), such as TIN2 
(Fig. 7 C2, top). This effect of GNL3L in retaining telomeric 
TRF1 is observed mainly in telomerase
+ cells and predicts that 
GNL3L may have a negative impact on telomere elongation in 
those cells, which indeed is the case in HTC75 cells shown by 
Fu and Collins (2007).
In telomerase
 ALT cells, telomere elongation is achieved 
by homologous recombination. In those cells, GNL3L is capable 
of reducing the PML body recruitment of TRF1
+ and TRF2
+ foci, 
a process related to the recombination-based mechanism of telo-
mere elongation. GNL3L does so without affecting the level of 
SUMOylated TRF1 and therefore supports the recruitment model, 
which depicts that the SUMOylation of TRF1 occurs before its 
recruitment to the PML body (Potts and Yu, 2007) (Fig. 7 C2, 
bottom). Thus, our data support the notion that GNL3L stabilizes 
the telomeric TRF1 complex in telomerase
+ cells and prevents 
APB formation in telomerase
 cells, both of which are expected 
to inhibit telomere elongation. As the telomere plays a key role 
in limiting the number of cell division, human tumors usually 
develop an increased telomerase activity or the telomerase-
independent ALT mechanism to extend their proliferation with-
out entering into crisis of chromosome fusions and death. Given 
the ability of GNL3L in modulating TRF1 and telomere length, 
one would expect that its expression level might be reduced in 
cancer cells or at least balanced by its ability to promote cell cycle 
progression. In conclusion, this work exemplifies the great com-
plexity of telomere maintenance and cell cycle regulation.
Materials and methods
Cell culture, transfection, Western blot, and immunofluorescence
All these procedures were described in our previous studies (Tsai and 
McKay, 2005; Meng et al., 2007). Primary antibodies used in this study 
are anti-HA (HA.11), Myc (9E10), FLAG (M2), TRF1 (TRF-78, Santa Cruz 
Biotechnology, Inc.), TRF2 (4A794), PML (PG-M3 and H-238), -tubulin 
(Sigma-Aldrich), CENP-A (Millipore), and GNL3L (clone #134).
Coimmunoprecipitation
Cells were harvested in NTEN buffer. Lysates were incubated with primary 
antibody for 1 h, followed by incubation with protein G–Sepharose beads (GE 
Healthcare) for an additional 4 h at 4°C. Immunoprecipitates were washed 
three times with RIPA buffer before SDS-PAGE and Western detection.
GST pull-down assay
GST-fused proteins were expressed in BL21/DE3 by using the pGEX4T-2 
vector (Tsai and McKay, 2002). Epitope-tagged proteins were expressed 
Initially, our findings may seem contradictory to the idea that 
increasing TRF1 protein during mitosis creates tethered sister 
chromatids at the telomere and blocks the transition from meta-
phase to anaphase (Waizenegger et al., 2000; Dynek and Smith, 
2004; Canudas et al., 2007). Detailed confocal analyses help 
resolve this dilemma by revealing that TRF1 signals in the meta-
phase, anaphase, and early telophase cells are less concentrated 
at the telomere despite its protein level increase, compared with 
that in the interphase cells. This latter finding creates another 
paradox, as a previous study, based on an in vitro reconstituted 
system mimicking Xenopus early development, has shown that 
the telomeric DNA binding of TRF1 is strengthened during 
mitosis (Nishiyama et al., 2006). Therefore, the possibility of an 
epitope-masking  protein  modification  or  binding  that  causes 
failure to detect the telomeric TRF1 during mitosis by the anti-
TRF1 antibody needs to be addressed. We do so by showing that 
the GFP-tagged TRF1 and the endogenous TRF2 display the 
same pattern of distribution as does the endogenous TRF1 and 
that the overall TRF1 signal outside the telomere is relatively 
higher in the metaphase cell than in the interphase cell. It is 
worth noting that overexpression of TRF1-gfp at high levels still 
forces its accumulation at the telomere, which may cause teth-
ered chromosomes as reported previously, thereby leading to the 
same mitotic arrest phenotype as that of TRF1 depletion.
The metaphase-to-anaphase transition may not be the only 
event affected by GNL3L or TRF1 perturbation. The decrease of 
anaphase and telophase cell percentages is not accompanied by a 
concomitant increase of prophase and metaphase cells, suggest-
ing that GNL3L depletion may also block the prophase entry. 
Indeed, Western blots demonstrate an increased phospho-cdc2 
(p-cdc2, Tyr15) level associated with GNL3L knockdown. 
Furthermore, coexpression of TRF1 in the control knockdown 
HeLa cells and coexpression of G3L-siR in the GNL3L knock-
down HeLa and HEK293 cells both reduce the prophase cell per-
centage, supporting that the prophase entry of dividing cells may 
be sensitive to the levels of TRF1 and GNL3L as well. Finally, it 
should be noted that the cell cycle arrest effect and multipolar 
spindle phenotype of GNL3L depletion, although significant and 
consistent, is not absolute. So is the ability of TRF1 to rescue the 
GNL3L-depleted cell cycle phenotype in HeLa cells. The former 
finding may be due to incomplete knockdown of the GNL3L pro-
tein, and the latter result suggests that the cell cycle activity of 
GNL3L  may  involve  additional  TRF1-independent  pathways. 
Based on our work, we propose that when dividing cells proceed 
into metaphase, a portion of their TRF1 proteins is dissociated 
from the telomere to allow proper segregation of sister chroma-
tids. The telomere-dissociated TRF1 also performs a cell cycle 
regulatory function, but will be degraded unless bound by GNL3L 
(Fig. 7 C1). Therefore, knocking down the expression of GNL3L 
favors the ubiquitylation and degradation of TRF1 protein, which 
then leads to cell cycle arrest at the metaphase-to-anaphase tran-
sition and an increased number of cells with multipolar spindles. 
The increase of metaphase cells with multipolar spindles may 
suggest a role of TRF1 and GNL3L in regulating the homeostasis 
of centrosomes or microtubules. A connection between TRF1 
and microtubule polymerization has been reported by a previous 
study (Nakamura et al., 2001).JCB • VOLUME 185 • NUMBER 5 • 2009   838
at 0.5-s intervals for 45 s after photobleaching. For quantification, fluores-
cence intensities of the bleached area, the entire nucleus, and the area out-
side of the nucleus were measured. The relative fluorescence index (RFI) in 
the bleached area was normalized to the total intensity in the nucleus after 
background subtraction by using the following calculation: RFI = (It/I0) × 
(TN0/TNt), where It and I0 are the background-subtracted intensities of the 
bleached spot at time point t and before photobleaching, respectively, and 
TNt and TN0 are the background-subtracted intensities of the entire nucleus 
at time point t and before photobleaching, respectively. Cells with signal 
loss of more than 10% during the imaging phase were discarded. 40 cells 
of four independent experiments were analyzed.
Cell cycle profile analysis and synchronization
Cell cycle profiles were analyzed by counting the PI-labeled cells with a 
COULTER EPICS XL flow cytometer and the XL System II software (Beckman 
Coulter). Each cell cycle profile was compiled from 2 × 10
4 gated events, 
and analyzed using the Multi Cycle AV software (Phoenix Flow Systems). 
Early S phase synchronization was achieved by incubating the log-phase 
cells with 2 mM thymidine for 20 h. G2/M arrest was achieved by incuba-
tion with 0.5 µM nocodazole for 20 h.
Online supplemental material
Figure S1 shows control experiments confirming the specific interaction 
between TRF1 and GNL3L. Figure S2 describes the creation of shRNAmir-
based GNL3L knockdown and rescue constructs. Figure S3 validates the 
use of GFP-fused TRF1 for FRAP studies. Figure S4 summarizes the GNL3L 
effect on TRF1 SUMOylation. Figure S5 shows the subcellular distributions 
of TRF1, TRF2, and GNL3L during mitosis. Online supplemental material is 
available at http://www.jcb.org/cgi/content/full/jcb.200812121/DC1.
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in HEK293 cells and extracted in phosphate-buffered saline (PBS)/Triton 
X-100 (1%) buffer. Sepharose-bound GST fusion proteins (2 µg) were incu-
bated with cell lysates for 2 h and washed five times with PBS, including 
two times with high-salt solutions.
siRNA duplex, short hairpin siRNA, and inducible GNL3L knockdown cells
Transient knockdown experiments were performed by transfection of siRNA 
duplexes or shRNAmir constructs. Control and GNL3L-specific siRNA 
duplexes (siG3-1 and siG3-2) were described previously (Yasumoto et al., 
2007).  TRF1-specific  siRNA  duplex  targets  5-TGCCAGGAACTGCTC-
GAGT-3. shRNAmir constructs were generated in the pShag Magic vector 
(pSM2c) based on a mir-30 hairpin design that targets 21-bp sequences, 
capped by mir-5 and mir-3 sequences, and driven by a U6 promoter. The 
targeted sequences for GNL3L are: 5-CCAATCGAGAGGCTGAATTAA-3 
(shG3-a), 5-GGAGGAGATTTCCAACTATTA-3 (shG3-b), 5-GCTGTTCCT-
GGAATTACCAAA-3 (shG3-c), and 5-CCGCCCTAAGAGCAACAGTAT-3 
(shG3-d).  The  shScr  construct  targets  a  scrambled  sequence:  5-TCTC-
GCTTGGGCGAGAGTAAG-3. Creation of stable lines with inducible 
GNL3L knockdown capabilities is described in Fig. S2.
Chromatin immunoprecipitation
Cells were cross-linked by 1% formaldehyde, lysed in 50 mM Tris buffer-1% 
SDS, and sonicated to obtain chromatin fragments from 300 bp to 1 kb. 
The resulting lysates were incubated with primary antibodies and protein G– 
Sepharose for 8 h at 4°C. After extensive washes, chromosomal DNAs 
were extracted by treatments with Rnase A and proteinase K, and reverse 
cross-linking at 65°C. DNA samples were dot-blotted onto Hybond mem-
branes, hybridized with a 
32P-labeled (TTAGGG)4 or Alu (5-GGCCGGGC-
GCGGTGGCTCACGCCTGTAATCCCAGCA-3) oligonucleotide probe, and 
exposed to PhosphorImager screen. All lysates were normalized based on 
protein concentrations. A part of the lysate (1/20th) was used to measure 
the input DNA amount.
EMSA
EMSA experiments were performed with nuclear extracts prepared from 
HEK293 cells transfected with the indicated constructs. To generate EMSA 
probes, the (TTAGGG)6 primer was radiolabeled with -P
32 ATP in a T4 
kinase reaction, annealed with excess amounts of the (CCCTAA)6 primer, 
and purified through QIAquick nucleotide removal columns (QIAGEN). 
Reaction and gel electrophoresis conditions follow the same procedure 
described previously (Yasumoto et al., 2007).
Protein degradation and in vivo ubiquitination assays
Protein  degradation  assays  were  performed  in  cycloheximide-treated 
HEK293 cells as described previously (Zhu et al., 2006). For in vivo ubiq-
uitination assays, His-tagged ubiquitin and TRF1 expression plasmids were 
co-expressed in HEK293 cells. 2 d later, cells were treated with MG132 
(10 µM) for 6 h before protein extraction in 6M guanidinium buffer. Ubiq-
uitylated  proteins  were  pulled  down  by  Ni
2+-chelating  Sepharose  and 
washed extensively.
High-resolution confocal imaging of APB, TRF1, and mitotic cells
APBs were scored on the basis of colocalization of TRF1-gfp/PML (PG-M3) 
or TRF2 (4A794)/PML (H-238). Endogenous TRF1 was detected by a mono-
clonal (TRF-78) or polyclonal (C-19) antibody. Images were acquired by a 
confocal microscope (LSM510; Carl Zeiss, Inc.) with a 63X Plan-Apochromat 
oil objective (1.4 NA), and scanned with ≤1.0-µm optical thickness and 
0.5-µm interval along the Z-axis. For APB measurement, stacked images 
were collected from 95–100 cells of five independent experiments for every 
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Fluorescence recovery after photobleaching (FRAP)
Bleaching  experiments  were  performed  on  a  confocal  microscope 
(LSM510; Carl Zeiss, Inc.) equipped with a 63X Plan-Apochromat oil objec-
tive. The GFP signal was excited with the 488-nm argon laser (21-mW 
nominal output). Emission above 505 nm was monitored. Cells were main-
tained at 35°C with a heat blower during the entire course of recording. 
The  FRAP  paradigm  was  designed  such  that  a  single  telomere  was 
bleached by a short laser pulse administered at 70% of the power of the 
488-nm argon laser (21-mW nominal output) for three iterations which 
lasted for 256 ms. For image acquisition, the laser power was attenuated 
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